BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11146378)

  • 1. Growth hormone and osteoporosis: an overview of endocrinological and pharmacological insights from the Utah paradigm of skeletal physiology.
    Frost HM
    Horm Res; 2000; 54 Suppl 1():36-43. PubMed ID: 11146378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The "muscle-bone unit" in children and adolescents: a 2000 overview.
    Frost HM; Schönau E
    J Pediatr Endocrinol Metab; 2000 Jun; 13(6):571-90. PubMed ID: 10905381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From Wolff's law to the Utah paradigm: insights about bone physiology and its clinical applications.
    Frost HM
    Anat Rec; 2001 Apr; 262(4):398-419. PubMed ID: 11275971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changing views about 'Osteoporoses' (a 1998 overview).
    Frost HM
    Osteoporos Int; 1999; 10(5):345-52. PubMed ID: 10591831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Muscle, bone, and the Utah paradigm: a 1999 overview.
    Frost HM
    Med Sci Sports Exerc; 2000 May; 32(5):911-7. PubMed ID: 10795780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The benefit of combining non-mechanical agents with mechanical loading: a perspective based on the Utah Paradigm of Skeletal Physiology.
    Jee WS; Tian XY
    J Musculoskelet Neuronal Interact; 2005 Jun; 5(2):110-8. PubMed ID: 15951626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Utah paradigm of skeletal physiology: an overview of its insights for bone, cartilage and collagenous tissue organs.
    Frost HM
    J Bone Miner Metab; 2000; 18(6):305-16. PubMed ID: 11052462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of growth hormone in glucocorticoid-induced osteoporosis.
    Lombardi G; Colarusso S; Di Somma C; Guerra E; Tauchmanova L; Colao A
    J Endocrinol Invest; 2008 Jul; 31(7 Suppl):38-42. PubMed ID: 18791350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone and bone.
    Tritos NA; Biller BM
    Curr Opin Endocrinol Diabetes Obes; 2009 Dec; 16(6):415-22. PubMed ID: 19770650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coming changes in accepted wisdom about "osteoporosis".
    Frost HM
    J Musculoskelet Neuronal Interact; 2004 Mar; 4(1):78-85. PubMed ID: 15615080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cybernetic aspects of bone modeling and remodeling, with special reference to osteoporosis and whole-bone strength.
    Frost HM
    Am J Hum Biol; 2001; 13(2):235-48. PubMed ID: 11460869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seeking genetic causes of "osteoporosis:" insights of the Utah paradigm of skeletal physiology.
    Frost HM
    Bone; 2001 Nov; 29(5):407-12. PubMed ID: 11704489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hormones and osteoporosis update. Growth hormone and bone].
    Tanaka H
    Clin Calcium; 2009 Jul; 19(7):984-9. PubMed ID: 19567995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is increase in bone mineral content caused by increase in skeletal muscle mass/strength in adult patients with GH-treated GH deficiency? A systematic literature analysis.
    Klefter O; Feldt-Rasmussen U
    Eur J Endocrinol; 2009 Aug; 161(2):213-21. PubMed ID: 19439507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures.
    Schacht E; Richy F; Reginster JY
    J Musculoskelet Neuronal Interact; 2005; 5(3):273-84. PubMed ID: 16172518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatopause: dismetabolic and bone effects.
    Lombardi G; Tauchmanova L; Di Somma C; Musella T; Rota F; Savanelli MC; Colao A
    J Endocrinol Invest; 2005; 28(10 Suppl):36-42. PubMed ID: 16550721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does running strengthen bone?
    Boudenot A; Achiou Z; Portier H
    Appl Physiol Nutr Metab; 2015 Dec; 40(12):1309-12. PubMed ID: 26562001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth hormone and insulin-like growth factors as anabolic therapies for osteoporosis.
    Eriksen EF; Kassem M; Brixen K
    Horm Res; 1993; 40(1-3):95-8. PubMed ID: 8300056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GH and IGF-I as therapeutic agents for osteoporosis.
    Agnusdei D; Gentilella R
    J Endocrinol Invest; 2005; 28(8 Suppl):32-6. PubMed ID: 16323827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in bone mechanical strength in response to physical therapy.
    Ksiezopolska-Orłowska K
    Pol Arch Med Wewn; 2010 Sep; 120(9):368-73. PubMed ID: 20864911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.